Bicara Therapeutics Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-09 meeting.
“Proposal 2: Ratification of KPMG LLP The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows: Votes For Votes Against Votes Abstaining Ratification of appointment of KPMG LLP 55,914,602 8,815 1,570”
Shareholder Votes
Bicara Therapeutics Inc. shareholders approved Election of Class II Directors at the 2026-06-09 meeting.
“Proposal 1: Election of Directors The Company's stockholders elected each of the following individuals to serve as class II directors for a three-year term ending at the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows: Director Votes For Votes Withheld Broker Non-Votes Christopher Bowden, M.D. 48,558,710 5,145,418 2,220,859 Carolyn Ng, Ph.D. 47,431,269 6,272,859 2,220,859”
Earnings Releases
Bicara Therapeutics Inc. reported the first quarter ended March 31, 2026 results: net income Net loss totaled $56.2 million for the first quarter of 2026.
“Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026”
Earnings Releases
Bicara Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss totaled $37.4 million and $138.0 million for the fourth quarter and full year ended December 31, 2025, respecti.
“On March 30, 2026, Bicara Therapeutics Inc. (the "Company") issued a press release announcing its financial results and business highlights for the fiscal year and quarter ended December 31, 2025.”
Material Agreements
Bicara Therapeutics Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (effective 2026-02-24).
“On February 24, 2026, Bicara Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”)”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.